GM22193
LCL from B-Lymphocyte
Description:
BARTH SYNDROME; BTHS
TAFAZZIN; TAZ
|
Repository
|
NIGMS Human Genetic Cell Repository
|
| Subcollection |
Heritable Diseases |
|
Biopsy Source
|
Peripheral vein
|
|
Cell Type
|
B-Lymphocyte
|
|
Tissue Type
|
Blood
|
|
Transformant
|
Epstein-Barr Virus
|
|
Sample Source
|
LCL from B-Lymphocyte
|
|
Family History
|
N
|
|
Relation to Proband
|
proband
|
|
Confirmation
|
Molecular characterization before cell line submission to CCR
|
|
Species
|
Homo sapiens
|
|
Common Name
|
Human
|
|
Remarks
|
|
| IDENTIFICATION OF SPECIES OF ORIGIN |
Species of Origin confirmed by LINE assay |
| |
| Gene |
TAZ |
| Chromosomal Location |
Xq28 |
| Allelic Variant 1 |
L166X; BARTH SYNDROME |
| Identified Mutation |
LEU166TER |
| Remarks |
Clinically affected; two affected brothers (one deceased); neutropenia; fatigue; cardiomyopathy; donor subject is hemizygous for a T>A change in exon 6 of the TAZ (G4.5) gene [c.498T>A] resulting in a premature stop codon [Leu166Ter (L166X)] |
| Zegallai HM, Hatch GM, Impaired surface marker expression in stimulated Epstein-Barr virus transformed lymphoblasts from Barth Syndrome patients Scientific reports12:6195 2022 |
| PubMed ID: 35418665 |
| |
| Chan JZ, Fernandes MF, Steckel KE, Bradley RM, Hashemi A, Groh MR, Sciaini G, Stark KD, Duncan RE, N-oleoylethanolamide treatment of lymphoblasts deficient in Tafazzin improves cell growth and mitochondrial morphology and dynamics Scientific reports12:9466 2021 |
| PubMed ID: 35676289 |
| Split Ratio |
1:3 |
| Temperature |
37 C |
| Percent CO2 |
5% |
| Percent O2 |
AMBIENT |
| Medium |
Roswell Park Memorial Institute Medium 1640 with 2mM L-glutamine or equivalent |
| Serum |
15% fetal bovine serum Not Inactivated |
| Substrate |
None specified |
| Subcultivation Method |
dilution - add fresh medium |
| Supplement |
- |
|
|